X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Royalty Pharma gain rights for AG-881 (vorasidenib), an oral, selective, highly brain-penetrant dual inhibitor of mutant IDH1/2 enzymes for the treatment of IDH-mutant diffuse glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Agios Pharmaceuticals
Deal Size: $905.0 million Upfront Cash: $905.0 million
Deal Type: Agreement May 28, 2024
Details:
The collaboration providing capital to support the commercialization of CK-3773274 (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-3773274
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Cytokinetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 22, 2024
Details:
Through the acquisition, Royalty pharma gains royalties and milestones on SAR441344 (frexalimab), a first-in-class, second generation anti-CD40 ligand monoclonal antibody, for the treatment of multiple sclerosis.
Lead Product(s): Frexalimab
Therapeutic Area: Neurology Product Name: SAR441344
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: ImmuNext Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 09, 2024
Details:
Through the license agreement, Royalty Pharma will utilize the investigational product AMG 890 (olpasiran), currently undergoing evaluation in early-stage clinical trials, for treating elevated lipoprotein(a).
Lead Product(s): Olpasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 890
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Arrowhead Pharmaceuticals
Deal Size: $410.0 million Upfront Cash: $250.0 million
Deal Type: Licensing Agreement May 02, 2024
Details:
The collaboration aims to accelerate the clinical research program for Teva’s TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: TEV-‘749
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Teva Pharmaceutical Industries
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 13, 2023
Details:
Under the agreement, Royalty Pharma acquires additional royalties on Evrysdi (risdiplam), a survival motor neuron 2 splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival motor neuron protein deficiency.
Lead Product(s): Risdiplam
Therapeutic Area: Genetic Disease Product Name: Evrysdi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: PTC Therapeutics
Deal Size: $1,500.0 million Upfront Cash: $1,000.0 million
Deal Type: Agreement October 19, 2023
Details:
The proceeds will support continued development and commercialization of Endocrine Rare Disease products, including SKYTROFA (lonapegsomatropin-tcgd), a prodrug of somatropin, administered once weekly, and designed to provide sustained release of active, unmodified somatropin.
Lead Product(s): lonapegsomatropin-tcgd
Therapeutic Area: Endocrinology Product Name: Skytrofa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Ascendis Pharma
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 05, 2023
Details:
Under the agreement, Royalty Pharma is acquiring a 5.1 percentage royalty on net sales of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC, in the United States.
Lead Product(s): Nadofaragene Firadenovec-vncg
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Ferring Pharmaceuticals
Deal Size: $500.0 million Upfront Cash: $300.0 million
Deal Type: Agreement August 23, 2023
Details:
Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Karuna Therapeutics
Deal Size: $500.0 million Upfront Cash: $100.0 million
Deal Type: Agreement March 23, 2023
Details:
Pfizer has given Royalty Pharma an accelerated milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant). Zavzpret was approved by the U.S. FDA, which provides another important new treatment option for migraine patients.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Product Name: Zavzpret
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $475.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
